GIVAUDAN-ROURE SUBMITS PARSOL 1789 SAFETY DATA
This article was originally published in The Rose Sheet
Executive Summary
GIVAUDAN-ROURE SUBMITS PARSOL 1789 SAFETY DATA in combination products to FDA Sept. 8. The submission includes five clinical studies and two guinea pig studies sponsored by Givaudan-Roure customers outside the U.S., as well as other data intended to support Category I listing of the broad-spectrum sunscreen. The data are intended to bolster the company's citizen petition seeking monograph status for Parsol 1789 (avobenzone).